Wells Fargo & Company Tcr2 Therapeutics Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.0 - $1.62 $14,004 - $22,686	14,004 Added 52.48%	40,688 $61,000
Q4 2022 Feb 13, 2023	BUY	$0.83 - $1.44 $13,670 - $23,718	16,471 Added 161.27%	26,684 $26,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $6,227 - $12,555	3,348 Added 48.77%	10,213 $18,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $2.94 $9,995 - $13,926	-4,737 Reduced 40.83%	6,865 $20,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $25,653 - $50,345	-10,689 Reduced 47.95%	11,602 $32,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $338 - $617	74 Added 0.33%	22,291 $104,000
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $366,532 - $796,903	-43,428 Reduced 66.16%	22,217 $189,000
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $74,238 - $111,788	4,524 Added 7.4%	65,645 $1.08 Million
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $523,113 - $874,508	25,668 Added 72.4%	61,121 $1.35 Million
Q4 2020 Feb 09, 2021	BUY	$19.0 - $32.63 $36,119 - $62,029	1,901 Added 5.67%	35,453 $1.1 Million
Q3 2020 Nov 05, 2020	SELL	$13.1 - $20.69 $228,974 - $361,640	-17,479 Reduced 34.25%	33,552 $682,000
Q2 2020 Aug 13, 2020	BUY	$6.51 - $16.85 $194,512 - $503,461	29,879 Added 141.26%	51,031 $783,000
Q1 2020 May 14, 2020	BUY	$6.01 - $16.01 $127,123 - $338,643	21,152 New	21,152 $163,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.